^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Squamous Non-Small Cell Cancer

    Related cancers:
    Apply
    A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) (NCT07190248)
    Phase 3
    Merck Sharp & Dohme LLC
    Not yet recruiting
    Last update posted :
    09/24/2025
    Initiation :
    10/27/2025
    Primary completion :
    12/07/2029
    Completion :
    08/06/2032
    PD-L1 • KRAS
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • calderasib (MK-1084)
    A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (NCT07174908)
    Phase 3
    InxMed (Shanghai) Co., Ltd.
    Not yet recruiting
    Last update posted :
    09/16/2025
    Initiation :
    09/01/2025
    Primary completion :
    09/01/2028
    Completion :
    09/01/2030
    KRAS
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed • Anfangning (garsorasib) • ifebemtinib (IN10018)
    AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment (AGA TKI NSCLC) (NCT07158840)
    Phase 2
    Akeso
    Not yet recruiting
    Last update posted :
    09/08/2025
    Initiation :
    09/05/2025
    Primary completion :
    09/01/2028
    Completion :
    06/01/2029
    PD-L1
    |
    Idafang (ivonescimab)
    Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (NCT07020065)
    Phase 2
    Swiss Group for Clinical Cancer Research
    Not yet recruiting
    Last update posted :
    06/13/2025
    Initiation :
    11/01/2025
    Primary completion :
    03/01/2028
    Completion :
    03/01/2030
    PD-L1
    |
    carboplatin • gemcitabine • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc)
    A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer (NCT06984588)
    Phase 2/3
    TJ Biopharma Co., Ltd.
    Recruiting
    Last update posted :
    05/22/2025
    Initiation :
    03/28/2024
    Primary completion :
    08/05/2028
    Completion :
    09/30/2028
    PD-L1 • BRAF
    |
    Keytruda (pembrolizumab) • Loqtorzi (toripalimab-tpzi) • uliledlimab (TJD5)
    A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients (PULMO-01) (NCT06879717)
    Phase 1/2
    iOnctura
    Recruiting
    Last update posted :
    05/13/2025
    Initiation :
    04/22/2025
    Primary completion :
    01/01/2027
    Completion :
    01/01/2028
    IL7R
    |
    docetaxel • Jemperli (dostarlimab-gxly) • roginolisib (IOA-244)
    Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (NRG-LU003) (NCT03737994)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/25/2019
    Primary completion :
    07/21/2021
    Completion :
    12/02/2025
    MET
    |
    ALK positive • MET amplification • ALK rearrangement
    |
    cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)
    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 (NCT04613596)
    Phase 2/3
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/02/2020
    Primary completion :
    10/31/2028
    Completion :
    10/31/2029
    PD-L1 • KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Krazati (adagrasib)
    Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (NCT04181060)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/28/2020
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial (ACCIO) (NCT04267848)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/16/2020
    Primary completion :
    12/15/2025
    Completion :
    12/15/2025
    EGFR • PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • liposomal gemcitabine (FF-10832) • Pembroria (pembrolizumab biosimilar)
    Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) (NCT03829319)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    02/21/2025
    Initiation :
    03/25/2019
    Primary completion :
    08/11/2023
    Completion :
    08/30/2024
    EGFR • ALK • ROS1
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Lenvima (lenvatinib) • pemetrexed
    A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (ARTEMIDE-Lung03) (NCT06627647)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/27/2024
    Primary completion :
    05/10/2029
    Completion :
    03/25/2030
    PD-L1
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • rilvegostomig (AZD2936)